google_counter
Treatment of acute lymphoblastic leukemia (ALL) with CAR T-cell therapy (666397) | University Hospital Hamburg-Eppendorf - BookingHealth
{"translation_price":"50","translation_doc_price":"40","child_coefficient":"1.1","transfer_price":"2.00","transfer_price_vip":"5.00","constant_transfer_price_vip":350,"constant_transfer_price":150,"constant_transfer_distanse":60,"type":"treatment","program_full_story":"<ul>\n\t<li>Initial presentation in the clinic<\/li>\n\t<li>Clinical history taking<\/li>\n\t<li>Physical examination<\/li>\n\t<li>Review of medical records<\/li>\n\t<li>Laboratory tests:\n\t<ul>\n\t\t<li>Complete blood count<\/li>\n\t\t<li>General urine analysis<\/li>\n\t\t<li>Biochemical blood test (kidney and liver function tests)<\/li>\n\t\t<li>Indicators of inflammation (CRP, ESR)<\/li>\n\t\t<li>Indicators of blood coagulation<\/li>\n\t\t<li>Immunohistochemical and genetic analysis of tumor cells (if indicated)<\/li>\n\t<\/ul>\n\t<\/li>\n\t<li>Leukapheresis, processing of T-cells and cultivation of CAR T-cells<\/li>\n\t<li>Adjuvant chemotherapy<\/li>\n\t<li>Infusion of modified CAR T-cells to a patient<\/li>\n\t<li>Control examinations<\/li>\n\t<li>Cost of essential medicines and materials<\/li>\n\t<li>Nursing services<\/li>\n\t<li>Full hospital accommodation<\/li>\n\t<li>Explanation of future recommendations<\/li>\n<\/ul>\n<div class=\"program_indications_for_surgery\"><h4>Indications<\/h4><ul>\n\t<li>Acute lymphoblastic leukemia (ALL) that is resistant to the conventional therapy<\/li>\n<\/ul>\n<\/div><div class=\"program_how_program_going mt-4\"><h4>How program is carried out<\/h4><p style=\"text-align: justify;\"><strong>Days 1-2<\/strong>. Initial presentation at the clinic. The doctor collects the patient&#39;s medical history, looks at his medical records and previous examinations. Special attention is paid to previous cancer treatments and their results, since CAR T-cell therapy is indicated only if the conventional treatment protocols are ineffective. Based on the results of the consultation, the doctor administers the examination, which includes a complete blood count with white blood cell count, assessment of liver and kidney function, immunohistochemical and genetic analysis of tumor cells (if indicated) and other studies.<\/p>\n\n<p style=\"text-align: justify;\"><strong>Day 3<\/strong>. Collecting patient&rsquo;s blood. During the leukapheresis procedure, doctors harvest at least 100 million T-cells, which will subsequently undergo gene modification. If there are certain clinical reasons, and the patient needs to postpone the subsequent stages of CAR T-cell therapy, the harvested T-cells undergo the procedure of cryoconservation. If the patient is able to continue treatment immediately, then the harvested T-cells are transferred to the laboratory.<\/p>\n\n<p style=\"text-align: justify;\"><strong>Days 4-12<\/strong>. Processing and gene modification of the T-cells pool lasts 7-10 days. During this time, the patient is receiving immunosuppressive chemotherapy drugs. The chemotherapy is aimed at suppressing the patient&#39;s own immune system, which will allow CAR T-cells to fight the tumor more effectively.<\/p>\n\n<p style=\"text-align: justify;\"><strong>Day 13<\/strong>. Manufactured CAR T-cells are tested for the microbiological safety and functional activity. After the successful testing completion, the solution with CAR T-cells is administered to the patient intravenously.<\/p>\n\n<p style=\"text-align: justify;\"><strong>Day 14 and other days<\/strong>. Control examination and further medical supervision in the hospital are carried out. If there are no side effects of CAR T-cell therapy, a stable tendency towards normalization of blood count is observed and the patient has stable general health condition, the patient is discharged from the hospital. Before the discharge, the patient receives the detailed recommendations for further follow-up during the disease remission.<\/p>\n<\/div><div class=\"program_required_documents mt-4\"><h4>Required documents<\/h4><ul>\n\t<li>Complete blood count with white blood cell count<\/li>\n\t<li>Biochemical blood test (renal and liver function tests), if available<\/li>\n\t<li>Bone marrow biopsy results<\/li>\n\t<li>CT scan, if available<\/li>\n<\/ul>\n<\/div>","program_full_story_crm":"<ul>\n\t<li>Initial presentation in the clinic<\/li>\n\t<li>Clinical history taking<\/li>\n\t<li>Physical examination<\/li>\n\t<li>Review of medical records<\/li>\n\t<li>Laboratory tests:\n\t<ul>\n\t\t<li>Complete blood count<\/li>\n\t\t<li>General urine analysis<\/li>\n\t\t<li>Biochemical blood test (kidney and liver function tests)<\/li>\n\t\t<li>Indicators of inflammation (CRP, ESR)<\/li>\n\t\t<li>Indicators of blood coagulation<\/li>\n\t\t<li>Immunohistochemical and genetic analysis of tumor cells (if indicated)<\/li>\n\t<\/ul>\n\t<\/li>\n\t<li>Leukapheresis, processing of T-cells and cultivation of CAR T-cells<\/li>\n\t<li>Adjuvant chemotherapy<\/li>\n\t<li>Infusion of modified CAR T-cells to a patient<\/li>\n\t<li>Control examinations<\/li>\n\t<li>Cost of essential medicines and materials<\/li>\n\t<li>Nursing services<\/li>\n\t<li>Full hospital accommodation<\/li>\n\t<li>Explanation of future recommendations<\/li>\n<\/ul>\n<div class=\"program_indications_for_surgery\"><h4>Indications<\/h4><ul>\n\t<li>Acute lymphoblastic leukemia (ALL) that is resistant to the conventional therapy<\/li>\n<\/ul>\n<\/div><div class=\"program_how_program_going mt-4\"><h4>How program is carried out<\/h4><p style=\"text-align: justify;\"><strong>Days 1-2<\/strong>. Initial presentation at the clinic. The doctor collects the patient&#39;s medical history, looks at his medical records and previous examinations. Special attention is paid to previous cancer treatments and their results, since CAR T-cell therapy is indicated only if the conventional treatment protocols are ineffective. Based on the results of the consultation, the doctor administers the examination, which includes a complete blood count with white blood cell count, assessment of liver and kidney function, immunohistochemical and genetic analysis of tumor cells (if indicated) and other studies.<\/p>\n\n<p style=\"text-align: justify;\"><strong>Day 3<\/strong>. Collecting patient&rsquo;s blood. During the leukapheresis procedure, doctors harvest at least 100 million T-cells, which will subsequently undergo gene modification. If there are certain clinical reasons, and the patient needs to postpone the subsequent stages of CAR T-cell therapy, the harvested T-cells undergo the procedure of cryoconservation. If the patient is able to continue treatment immediately, then the harvested T-cells are transferred to the laboratory.<\/p>\n\n<p style=\"text-align: justify;\"><strong>Days 4-12<\/strong>. Processing and gene modification of the T-cells pool lasts 7-10 days. During this time, the patient is receiving immunosuppressive chemotherapy drugs. The chemotherapy is aimed at suppressing the patient&#39;s own immune system, which will allow CAR T-cells to fight the tumor more effectively.<\/p>\n\n<p style=\"text-align: justify;\"><strong>Day 13<\/strong>. Manufactured CAR T-cells are tested for the microbiological safety and functional activity. After the successful testing completion, the solution with CAR T-cells is administered to the patient intravenously.<\/p>\n\n<p style=\"text-align: justify;\"><strong>Day 14 and other days<\/strong>. Control examination and further medical supervision in the hospital are carried out. If there are no side effects of CAR T-cell therapy, a stable tendency towards normalization of blood count is observed and the patient has stable general health condition, the patient is discharged from the hospital. Before the discharge, the patient receives the detailed recommendations for further follow-up during the disease remission.<\/p>\n<\/div>","is_ambulant":"0","bh_fee":"0","only_for_children":"0","no_service":"0","with_prepayment":"1","show_calculator":"1","paket_type":"1","btn_type":"0","clinic_icon":"600042302dbdb.jpg","city":"Hamburg","clinic_site":"https:\/\/www.uke.de\/","department_recommend":"1","country":"Germany","country_id":"1","clinic_name":"University Hospital Hamburg-Eppendorf","cinic_name":"University Hospital Hamburg-Eppendorf","department_id":"1399","duration":"21","direction":"Hematology","min_duration":0,"clinic_id":"849","paketPrice":36000,"paket":"<ul>\n <li>Interpreter up to 80 hours<\/li>\n <li>Translation up to 15 pages<\/li>\n <li>Visa support<\/li>\n<\/ul>","title":"Treatment of acute lymphoblastic leukemia (ALL) with CAR T-cell therapy","price":{"val":495691.99,"type":"val"},"price_surcharge":0,"price_surcharge_clear":0,"extra_service_clinic":[{"id":"need_to_use_head_doctor","title":"Treatment by leading experts","type":"val","val":null,"req":0},{"id":"1_person_room","title":" Single room (whole period)","parent":"duration","type":"count_val","val":"140.00"},{"id":"2_person_room","title":" double room (whole period)","parent":"duration","type":"count_val","val":"70.00"},{"id":"attendant_place","title":"Accommodation for the accompanying person ","parent":"duration","type":"count_val","val":"90.00"}],"extra_service":[],"translation_hours":"0","translation_doc_count":null,"roads":[{"id":"9","distance":"7","airport_title":"Hamburg"},{"id":"24","distance":"123","airport_title":"Bremen"},{"id":"8","distance":"282","airport_title":"Berlin"}],"pakets":[],"lang":{"day":"Day","days":"days","ambulatory":"Outpatient","stationaryProgram":"Inpatient"}}

Treatment of acute lymphoblastic leukemia (ALL) with CAR T-cell therapy in University Hospital Hamburg-Eppendorf

University Hospital Hamburg-Eppendorf

Hamburg, Germany
Program id # 666397
Doctor photo
Prof. Dr. med. Carsten Bokemeyer
Department of Hematology, Oncology and Pulmonology
Specialized in: hematology, oncology, pulmonology

The program includes:

  • Initial presentation in the clinic
  • Clinical history taking
  • Physical examination
  • Review of medical records
  • Laboratory tests:
    • Complete blood count
    • General urine analysis
    • Biochemical blood test (kidney and liver function tests)
    • Indicators of inflammation (CRP, ESR)
    • Indicators of blood coagulation
    • Immunohistochemical and genetic analysis of tumor cells (if indicated)
  • Leukapheresis, processing of T-cells and cultivation of CAR T-cells
  • Adjuvant chemotherapy
  • Infusion of modified CAR T-cells to a patient
  • Control examinations
  • Cost of essential medicines and materials
  • Nursing services
  • Full hospital accommodation
  • Explanation of future recommendations

Indications

  • Acute lymphoblastic leukemia (ALL) that is resistant to the conventional therapy

How program is carried out

Days 1-2. Initial presentation at the clinic. The doctor collects the patient's medical history, looks at his medical records and previous examinations. Special attention is paid to previous cancer treatments and their results, since CAR T-cell therapy is indicated only if the conventional treatment protocols are ineffective. Based on the results of the consultation, the doctor administers the examination, which includes a complete blood count with white blood cell count, assessment of liver and kidney function, immunohistochemical and genetic analysis of tumor cells (if indicated) and other studies.

Day 3. Collecting patient’s blood. During the leukapheresis procedure, doctors harvest at least 100 million T-cells, which will subsequently undergo gene modification. If there are certain clinical reasons, and the patient needs to postpone the subsequent stages of CAR T-cell therapy, the harvested T-cells undergo the procedure of cryoconservation. If the patient is able to continue treatment immediately, then the harvested T-cells are transferred to the laboratory.

Days 4-12. Processing and gene modification of the T-cells pool lasts 7-10 days. During this time, the patient is receiving immunosuppressive chemotherapy drugs. The chemotherapy is aimed at suppressing the patient's own immune system, which will allow CAR T-cells to fight the tumor more effectively.

Day 13. Manufactured CAR T-cells are tested for the microbiological safety and functional activity. After the successful testing completion, the solution with CAR T-cells is administered to the patient intravenously.

Day 14 and other days. Control examination and further medical supervision in the hospital are carried out. If there are no side effects of CAR T-cell therapy, a stable tendency towards normalization of blood count is observed and the patient has stable general health condition, the patient is discharged from the hospital. Before the discharge, the patient receives the detailed recommendations for further follow-up during the disease remission.

Required documents

  • Complete blood count with white blood cell count
  • Biochemical blood test (renal and liver function tests), if available
  • Bone marrow biopsy results
  • CT scan, if available

Service

Price from:
Type of program :
Price for 1 day:
Expected duration of the program:
The minimum duration of the program:
Select

You may also book:

Hospital directly:
Saving:
Guarantee BookingHealth Price from:

About the department

According to the Focus magazine, the Department of Hematology, Oncology and Pulmonology at the University Hospital Hamburg-Eppendorf ranks among the top medical facilities in Germany specializing in bowel cancer treatment!

The department offers the full range of modern diagnostics and treatment of solid tumors, benign and malignant blood and hematopoietic system diseases, including bleeding disorders, as well as pathologies of the lungs and other organs of the respiratory system. The offer is complemented by effective palliative care. All physicians of the department are highly qualified experts in their area of specialization and apply theoretical knowledge and clinical experience to ensure an optimal therapy result. The department is headed by Prof. Dr. med. Carsten Bokemeyer.

In the field of hematology and oncology, of particular interest is the diagnostics and treatment of blood cancer (leukemias), lymphomas, gonadal tumors (for example, testicular cancer), malignancies of the digestive system, such as esophageal, stomach, pancreatic and colon cancer, cancer of the respiratory tract (lung cancer), connective tissue (sarcoma), as well as bleeding disorders. The pulmonary spectrum covers all diagnostic options, including interventional endoscopy and therapy. There is a unique experience in the treatment of pulmonary hypertension, cystic fibrosis, interstitial lung diseases.

An integral part of the department’s work is interdisciplinary cooperation with related doctors, such as radiologists, surgeons, radiation therapists, otolaryngologists, dermatologists, etc. An important role is also played by cooperation with all partners in the University Cancer Center Hamburg, as well as with international partners.

The department specializes in the diagnostics and treatment of the following diseases:

  • Oncology
    • Biliopancreatic tumors
    • Lymphomas of the central nervous system
    • Gastrointestinal tumors
    • Brain tumors
    • Testicular tumors
    • Head and neck tumors
    • Myelomas
    • Amyloidosis
    • Kidney cancer
    • Prostate cancer
    • Sarcomas
  • Hematology
    • Acute myeloid leukemia
    • Chronic lymphocytic leukemia
    • Chronic myeloid leukemia
    • Myeloproliferative neoplasia
    • Blood clotting disorders
    • Lymphomas
    • Myelodysplastic syndrome
    • Paroxysmal nocturnal hemoglobinuria
    • Thalassemia
  • Pulmonology
    • Lung cancer
    • Pulmonary hypertension
    • Interstitial lung diseases
    • Pulmonary vascular diseases
    • Mediastinal diseases
    • Respiratory diseases
    • Pleural diseases
      • Pulmonary endoscopy
        • Bronchoscopy (for diagnostic and therapeutic purposes)
      • Pulmonary function testing
        • Capillary blood gas test
        • Spirometry
        • Body plethysmography
        • Use of bronchodilators
        • Bronchial provocation test
        • Evaluation of lung diffusing capacity
        • Spiroergometry with the possibility of non-invasive heart rate monitoring
        • 6-min walk test
        • Sleep screening
  • Diagnostics and treatment of other diseases

Curriculum vitae

Education

  • 1989 Doctor of Medicine, Hannover Medical School, Hannover, Germany.
  • 1989 FMGEMS.
  • 1989 - 1995 Internship, Internal Medicine, Hannover Medical School, Hannover, Germany.
  • 1995 - 2004 Faculty Member, Department of Internal Medicine, Section of of Hematology, Oncology, Immunology, Rheumatology, University Hospital Tuebingen, Germany.

Academic Appointments and Achievements

  • 1999 Habilitation, Department of Internal Medicine, Hannover Medical School, Germany.
  • 2000 Nominated for C3 Professorship of Internal Medicine at the University of Muenster, Germany.
  • 2000 Associate Professor of Internal Medicine, University of Tuebingen.
  • 2004 Professor of Internal Medicine and Head of the Department of Hematology, Oncology and Pulmonology at the University Hospital Hamburg-Eppendorf.
  • 2007 Director of the University Cancer Center Hamburg.

Board Certification

  • 1993 Board certification, European Society for Medical Oncology.
  • 1995 Board certification, German Board of Internal Medicine.
  • 1997 Board certification, German Board of Internal Medicine (Hematology and Oncology).
  • 2000 Board certification, Quality Management in Medicine.

Memberships in Professional Societies

  • Since 1991 German Cancer Society (DKG).
  • Since 1991 Wilsede School of Oncology.
  • 1991 European Society of Medical Oncology (ESMO).
  • 1995 American Society of Clinical Oncology (ASCO).
  • 1995 German Society of Hematology/Oncology (DGHO).
  • 1998 German Association for Bone Marrow Transplantation (DAGKBT).

Honors and Awards

  • Fellowship of the German Academic Scholarship Fund.
  • Award of the Ministry of Science for Outstanding Student Achievements in Medicine.
  • 2000 National Award of the German Cancer Society.
  • 2000 Award for Experimental Urological Research, German Society of Urology.
  • 2001 Award of the Cancer Society of Baden Wuerttemberg.
  • 2001 Award of the German Society for Clinical Pharmacology.
  • 2002 Scientific Award for Medical Oncology.
  • 2006 Award of the University of Heidelberg (Anita and Cuno Wieland Award).

Committees

  • 1997 - 2004 Member of the Research Advisory Committee of the University of Tuebingen.
  • 2000 - 2004 Founding Member of the Comprehensive Cancer Center at the University of Tuebingen.
  • 2001 - 2004 Founding Member of the Interdisciplinary Center for Soft Tissue Sarcomas at the University of Tuebingen.
  • Since 2002 Chairman of the ESMO Examination Committee for Medical Oncology.
  • Since 2002 Board Member of the German Society of Hematology and Oncology.
  • Since 2005 Board Member of the German Cancer Society.
  • Since 2005 Board Member of the Cancer Society of Hamburg.

Photo of the doctor: (c) Universitätsklinikum Hamburg-Eppendorf (UKE) 


About hospital

According to the Focus magazine, the University Hospital Hamburg-Eppendorf is one of the top ten hospitals in Germany! 

Since its foundation in 1889, the hospital has taken a leading position in the European medical arena, which it still holds today. A highly competent medical team of more than 15,300 employees takes care of the health of patients. Approximately 2,900 of them are physicians and researchers, and more than 3,400 work as nurses and therapists. The hospital has 1,738 beds for inpatient treatment, and many diagnostic and therapeutic services are provided on an outpatient basis. A solid foundation for successful clinical practice in the medical complex is formed by a combination of research achievements with state-of-the-art equipment and the highest professionalism of doctors. In addition, the hospital has a modern and extremely comfortable infrastructure. The most important value for every employee of the University Hospital Hamburg-Eppendorf is the health and well-being of every patient.

The medical facility was the first university hospital in Europe to implement an electronic system for storing patient medical reports. As a result, all diagnostic and treatment protocols are stored electronically. In 2011, the hospital was certified as the first fully digital hospital in Europe.

The hospital represents all areas of modern medicine. The doctors of the healthcare facility have a wealth of theoretical knowledge and vast clinical experience, which allows them to easily cope with the treatment of both common and extremely rare, complex clinical cases. About 550,000 patients are treated here each year, over 450,000 of whom receive outpatient medical care.

An important part of the work of the University Hospital Hamburg-Eppendorf is research activities aimed at developing innovative diagnostic and treatment methods. The main areas of research of the hospital include neurobiology, oncology, cardiovascular research, and research on infectious and inflammatory diseases. Special attention is also given to research in molecular imaging and skeletal biology.

The hospital is distinguished by its first-class level of medical care, which is confirmed by numerous quality certificates of European and international standards: DIN EN IS0 9001 certificate, certificates of the German Cancer Society (DKG) in the treatment of breast cancer, colon cancer, gynecological cancer, prostate cancer, and other oncological diseases, certificate of the German Cardiac Society (DGK) in the treatment of acute coronary syndrome, certificate of the German Spine Society (DWG), and others.

Photo: (с) depositphotos

Accommodation in hospital

Patients rooms

The patients of the University Hospital Hamburg-Eppendorf live in comfortable single and double rooms designed in bright colors. Each room is equipped with an ensuite bathroom with a toilet and a shower. The standard room includes an automatically adjustable bed, a bedside table, a wardrobe, a table and chairs for receiving visitors, a telephone, a radio and a TV. Also, there is Wi-Fi access.

Meals and Menus

The patient and his accompanying person have a daily choice of three menus. If for any reason you do not eat all the food, you will be offered an individual menu. Please inform the medical staff about your dietary preferences prior to the treatment.

Further details

Standard rooms include:

Toilet
Shower
Wi-Fi
TV

Religion

Religious services are available upon request.

Accompanying person

During the inpatient program, an accompanying person may stay with you in a patient room or hotel of your choice.

Hospital accommodation

During the outpatient program, you may stay in a hotel at the hospital.

Hotel

During the outpatient program, you may stay in a hotel of your choice. Managers will help you choose the most suitable options.

The hospital offers a full range of laboratory tests (general, hormonal, tests for infections, antibodies, tumor markers, etc.), genetic tests, various modifications of ultrasound scans, CT scans, MRI and PET / CT, angiography, myelography, biopsy and other examinations. Treatment with medications, endoscopic and robotic operations, stereotaxic interventions is carried out here, modern types of radiation therapy are also used. The hospital offers patients all the necessary therapeutic techniques.

  • Coiling and clipping of aneurysms of different localizations
  • Transjugular intrahepatic portosystemic shunting in patients with portal hypertension
  • Minimally invasive surgeries (da Vinci)
  • Removal and reconstruction of mammary glands
  • Hyperthermic intraperitoneal chemotherapy (HIPEC)

These are arteriovenous malformations and angiomas, vascular aneurysms, pathologies of the mammary glands, pelvic organ prolapse, urinary incontinence, malignant tumors of various localizations (area of ​​​​special attention is treatment of intestinal cancer), pathologies of liver and pancreas, cataracts and rare ophthalmic pathologies (aphakia, aniridia ), infertility and other diseases.

  • Interventional neuroradiology
  • Mammology
  • Oncology
  • Gastroenterology
  • Surgery

Over 2,900 highly qualified physicians and researchers work at the hospital.